Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » QuanDx to Distribute Zeesan's High-Risk HPV Genotyping Assay in Europe

QuanDx to Distribute Zeesan's High-Risk HPV Genotyping Assay in Europe

Nov 25, 2015
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – QuanDx, a San Francisco-based biotechnology firm focused on personalized cancer diagnostics, has announced a worldwide distribution agreement with Zeesan Biotech for that firm's MeltPro High Risk HPV Genotyping Assay. The deal excludes China, and terms of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Even Bigger

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Got Into the Lab Machines

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Not Going to Pay

Science reports that a Dutch research funding agency is combating a ransomware attack.

Science Papers Present Haplotype-Resolved Genomes, MiRNA-Linked Complex Tied to Ribosomal Protein Production

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
25
Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

What's Popular?

In PCR

  1. Luminex Shares Surge on Rumor of Acquisition by DiaSorin

  2. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

  3. German Nucleic Acid Sample Prep Startup Rides COVID-19 Testing, Automation Waves

    Premium

  4. Walgreens to Sell Labcorp COVID-19 PCR Home Collection Kits Over-the-Counter

  5. Biocartis Reports 15 Percent Rise in 2020 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.